Building work to start at Chesterford Research Park
Construction on a new multimillion pound laboratory-focused hothouse at Chesterford Research Park will start this month.
Work on the Newnham Building is estimated to take 16 months with completion scheduled for May 2020.
Aimed at life science/technology R & D occupiers looking for grow-on space, the Newnham Building will create a detached two-storey laboratory/R & D building situated within a prominent position on the park and is said to be suitable for either single or multi-occupation.
The development will provide up to 37,500 sq ft of fully fitted laboratory and write-up space at the heart of the Cambridge biotech cluster. Arranged over ground and first floors, the building will also benefit from 111 parking spaces.
Internally, the building will provide a newly constructed double height glazed reception accessing the western entrance as well as a new portal to the eastern end of the building.
The first floor will have access to a new terrace overlooking the wider park and landscaped areas. Significant plant loft space makes the building capable of being occupied by a range of laboratory/R & D occupiers, either in part or as a whole. The flexibility of the building also gives it the capability to cater for a range of needs in terms of technical configuration, as well as sizing.
Julian Cobourne, senior asset manager, Aviva Investors – joint owner of Chesterford Research Park alongside Uttlesford District Council – said: “There is a clear requirement within the cluster for additional grow-on space and the Newnham Building will offer that next step up for companies looking to expand.
“The flexibility of the space makes it suitable for either single or multi-occupier layout and the fully-fitted nature of the laboratory space adds a level of plug-and-play convenience rarely seen at this level.
“Bringing forward the Newnham Building at this stage responds to the needs of a growing market and clearly bridges the gap between pure start-up space and the larger, more established life-science ventures.”
Martin Sylvester, director of The Churchmanor Estates Company Plc – Chesterford Research Park’s development partner – added: “The Newnham Building’s prominent position on the park, coupled with Chesterford’s excellent reputation within the cluster has meant we have already seen significant interest from current occupiers looking for grow-on space, as well as from ventures new to Chesterford Research Park.”
Chesterford Research Park provides an innovative, flexible and future proofed environment for both established and early stage biotechnology and pharmaceutical research and development companies including Arecor, AstraZeneca, Charles River Laboratories, Evonetix and Domainex.
To date, more than 300,000 sq ft of laboratory R & D space has been let and occupied. Further phases of construction are proposed to extend the development to approximately one million sq ft.